World Journal of Surgery and Surgical Research

Review Article
Published: 27 Aug, 2024

The Role of Immunotherapy in Enhancing Surgical Outcomes for Melanoma Patients

El-Tanani M[1], Rangraze I[2], Rabbani SA[1], Rizzo M[3], Parvez S[4] and Ahmed Khan M[5]*

[1]College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE

[2]Department of Internal Medicine, RAK College of Medical Sciences, RAK Medical and Health Sciences University, UAE

[3]Department of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, Italy

[4]Department of Toxicology, School of Chemical and Life Sciences, Jamia Hamdard, India

[5]School of Pharmaceutical Education and Research, Jamia Hamdard, India

Abstract

The integration of immunotherapy with surgical treatment represents a transformative approach to managing melanoma, one of the most aggressive forms of skin cancer. Immunotherapy, particularly immune checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors, has shown remarkable efficacy in inducing durable responses and improving survival rates in melanoma patients. This manuscript explores the synergistic potential of combining immunotherapy with surgical intervention to enhance treatment outcomes. Preoperative immunotherapy can shrink tumors, making them more resectable, while postoperative immunotherapy helps eradicate residual microscopic disease and reduce recurrence risk. Clinical trials, such as CheckMate 238 and KEYNOTE-054, have demonstrated significant improvements in recurrence-free survival with adjuvant immunotherapy. Neoadjuvant trials, including OpACIN and NADIM, have shown high rates of pathological complete response, transforming inoperable tumors into resectable ones. Despite the promising results, challenges such as patient selection, management of immune-related adverse effects, and cost accessibility need to be addressed. Personalized treatment plans based on predictive biomarkers are essential for optimizing outcomes. Case studies highlight the real-world benefits and complexities of this combined approach, emphasizing the importance of a multidisciplinary strategy. As research progresses, the continued refinement of immunotherapy and surgical techniques promises to set new standards in melanoma care, enhancing survival rates and quality of life for patients. This integrated approach represents a significant advancement in the fight against melanoma, offering hope for better management and eventual eradication of this aggressive cancer.

OPEN ACCESS

Correspondence:

Mohamed El-Tanani, College of Pharmacy, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, UAE,

Received Date: *04 Aug 2024*

Accepted Date: *22 Aug 2024*

Published Date: *27 Aug 2024*

Citation:

El-Tanani M, Rangraze I, Rabbani SA, Rizzo M, Parvez S, Ahmed Khan M. The Role of Immunotherapy in Enhancing Surgical Outcomes for Melanoma Patients. World J Surg Surgical Res. 2024; 7: 1567.

Copyright *© 2024 El-Tanani M. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.*



Graphical Abstract:

Introduction

Melanoma, a malignant tumor of melanocytes, represents one of the most aggressive forms of skin cancer. It accounts for a significant proportion of skin cancer-related deaths worldwide [1]. Despite advancements in early detection and surgical techniques, melanoma remains a clinical challenge due to its propensity for metastasis and recurrence. Traditionally, surgical resection has been the cornerstone of melanoma treatment, particularly for localized disease [2]. However, the limitations of surgery in advanced stages necessitate the exploration of adjunctive therapies to improve patient outcomes [3].

Immunotherapy has emerged as a revolutionary approach in the oncologic landscape, harnessing the body's immune system to target and eliminate cancer cells [4]. With the advent of immune checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors, immunotherapy has shown remarkable efficacy across various malignancies [5], including melanoma [6]. These agents have demonstrated the ability to induce durable responses and improve survival rates, even in patients with advanced disease [5].

Preoperative (neoadjuvant) immunotherapy can potentially shrink tumors, making them more resectable, while postoperative (adjuvant) immunotherapy can help eradicate residual microscopic disease and reduce the risk of recurrence [7,8]. Moreover, immunotherapy may modulate the tumor microenvironment, rendering cancer cells more susceptible to surgical eradication [9].

Furthermore, the neoadjuvant immunotherapy has been shown to increase the number of complete pathological responses, allowing for less extensive surgeries and preserving more normal tissue [10]. Additionally, the immune response elicited by immunotherapy may lead to a systemic anti-tumor effect, targeting micrometastases that are not detectable at the time of surgery [11]. These advancements highlight the importance of a multidisciplinary approach in managing melanoma, integrating the expertise of surgical oncologists, medical oncologists, and immunologists to optimize patient care [12,13].

This manuscript aims to provide a comprehensive overview of the role of immunotherapy in enhancing surgical outcomes for melanoma patients. We will explore into the historical evolution of melanoma treatment, the mechanisms of action of immunotherapeutic agents, and the synergistic effects of combining these modalities. Through a review of clinical trials, case studies, and emerging data, we will elucidate the benefits, challenges, and future directions of integrating immunotherapy with surgical treatment. Our goal is to highlight the potential of this combined approach to improve survival rates and quality of life for melanoma patients.

Historical Perspective

The treatment of melanoma has undergone significant evolution over the decades, marked by advancements in surgical techniques and the development of novel therapeutic approaches [14]. Historically, surgery has been the primary modality for managing melanoma, with wide local excision being the standard of care for localized disease [15]. The goal of surgery has always been to achieve clear margins, thereby reducing the likelihood of local recurrence [16]. In the early days, this often-involved extensive tissue removal, which sometimes resulted in significant morbidity for the patients [17].

As understanding of melanoma biology advanced, surgical techniques became more refined. The introduction of sentinel lymph node biopsy in the 1990s was a pivotal moment in melanoma surgery [18]. This minimally invasive procedure allowed for the accurate staging of the disease without the need for extensive lymph node dissection, thereby reducing complications and improving the quality of life for patients [19]. Sentinel lymph node biopsy remains a standard procedure for melanoma staging today [20].

Parallel to the advancements in surgical techniques, the field of immunotherapy began to take shape. The concept of harnessing the immune system to fight cancer can be traced back to the late 19th century when Dr. William Coley observed that infections could cause tumor regression [21]. However, it wasn't until the late 20th and early 21st centuries that significant breakthroughs were made. The discovery of immune checkpoints, such as PD-1 and CTLA-4, and the subsequent development of inhibitors targeting these pathways, revolutionized cancer treatment [22,23].

The first FDA-approved immune checkpoint inhibitor for melanoma was ipilimumab, an anti-CTLA-4 antibody, in 2011. This was followed by the approval of anti-PD-1 antibodies, nivolumab and pembrolizumab, which demonstrated superior efficacy and a better safety profile [24]. These agents have since become a cornerstone of melanoma treatment, particularly for advanced and metastatic disease.

As we look to the future, the lessons learned from past experiences and the ongoing advancements in both surgery and immunotherapy will likely lead to even more effective strategies for managing melanoma.

Mechanisms of Immunotherapy

Immunotherapy represents a paradigm shift in cancer treatment, leveraging the body's immune system to combat malignant cells [25]. The success of immunotherapy in melanoma, particularly through the use of immune checkpoint inhibitors, has been profound [26]. This section will explore the mechanisms by which immunotherapeutic agents' function, the specific role of immune checkpoints, and the synergistic potential of combining immunotherapy with surgical interventions.

Immune checkpoints are regulatory pathways in the immune system that maintain self-tolerance and modulate the duration and amplitude of physiological immune responses [27]. Tumor cells often exploit these checkpoints to avoid being attacked by the immune system [28]. Immune checkpoint inhibitors work by blocking these pathways, thereby allowing the immune system to recognize and destroy cancer cells more effectively [29]. Two primary checkpoints have been the focus of immunotherapy in melanoma: PD-1 (Programmed Death-1) and CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) [6].

PD-1 inhibitors, such as nivolumab and pembrolizumab, block the interaction between PD-1 receptors on T-cells and their ligands, PD-L1 or PD-L2, which are often overexpressed on tumor cells [5,30]. This blockade enhances T-cell activation and promotes an anti-tumor response. PD-1 inhibitors have shown significant efficacy in treating advanced melanoma, with improved response rates and survival outcomes compared to traditional therapies.

CTLA-4 inhibitors, like ipilimumab, work by blocking the CTLA-4 receptor on T-cells [31]. CTLA-4 competes with the stimulatory receptor CD28 for binding to CD80/CD86 on antigen-presenting cells [32] by outcompeting CD28, CTLA-4 dampens T-cell activation. Ipilimumab blocks this interaction, thereby enhancing



Figure 1: The figure illustrates the interaction between two primary immune checkpoints, PD-1 (Programmed Death-1) and CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4), and their respective ligands.

T-cell activation and proliferation [31,33]. Ipilimumab was the first immune checkpoint inhibitor approved for melanoma and has been shown to improve overall survival in patients with advanced disease [34] (Figure 1).

The combination of immunotherapy and surgery offers a multifaceted approach to melanoma treatment, exploiting the strengths of both modalities to improve patient outcomes [35].

The mechanisms by which immunotherapy enhances surgical outcomes are complex and multifaceted [36-40], involving direct anti-tumor effects, modulation of the tumor microenvironment, and the synergistic potential of combining neoadjuvant, intraoperative, and adjuvant approaches [41].

Immunotherapy can increase the infiltration of immune cells into the tumor microenvironment, promoting an anti-tumor response [42]. These agents can modulate the cytokine milieu within the tumor, further enhancing immune activation and reducing tumor-promoting signals [43]. Understanding these mechanisms is crucial for optimizing treatment strategies and improving outcomes for melanoma patients.

Preoperative Immunotherapy

Administering immunotherapy before surgery, known as neoadjuvant immunotherapy, is an emerging strategy that has shown promise in the treatment of melanoma. Neoadjuvant immunotherapy can convert unresectable tumors into resectable ones, which is a significant advantage for patients with advanced disease.

One of the primary benefits of neoadjuvant immunotherapy is its ability to elicit an early systemic immune response [44]. This not only targets the primary tumor but also addresses micrometastases that might not be detectable at the time of diagnosis [45]. By treating the disease systemically before surgical intervention, neoadjuvant immunotherapy can help to reduce the risk of recurrence and improve long-term outcomes [46]. Clinical trials have demonstrated that patients receiving neoadjuvant immunotherapy often achieve a higher rate of complete pathological responses, which correlates with better survival rates [10,46,47] (Figure 2).

Several case studies and clinical trials have provided compelling evidence for the effectiveness of neoadjuvant immunotherapy in melanoma. For instance, studies have shown that neoadjuvant treatment with immune checkpoint inhibitors, such as nivolumab and pembrolizumab, can lead to significant tumor reduction and even complete responses in some patients [48-51]. These promising results have sparked interest in further exploring and optimizing neoadjuvant regimens for melanoma and other cancers.

However, the integration of neoadjuvant immunotherapy into clinical practice also presents several challenges. Identifying the patients who are most likely to benefit from this approach is crucial. Biomarkers that predict response to immunotherapy can help in selecting appropriate candidates for neoadjuvant treatment [52]. Additionally, managing immune-related adverse effects is a critical aspect of care, as these can impact the timing and feasibility of subsequent surgery. Ongoing research and clinical trials continue to refine neoadjuvant strategies, aiming to maximize the therapeutic benefits while minimizing risks and complications.

Intraoperative Considerations

The integration of immunotherapy into the surgical management of melanoma requires careful consideration of intraoperative factors [53]. One of the primary ways immunotherapy influences surgical decision-making is through its impact on tumor characteristics. Surgeons must be prepared to adapt their techniques based on these alterations to optimize resection and minimize complications.

Managing immune-related adverse effects during surgery is another critical aspect of intraoperative care [54]. Immunotherapy



Figure 2: Illustrates the potential predictors of response to neoadjuvant immunotherapy.
PD: Programmed Death; T-reg: regulatory T cell; TCR: T Cell Receptor; MHC: Major Histocompatibility Complex; CD8: Cytotoxic T Lymphocytes

can trigger a range of side effects, including inflammation and autoimmune responses [55], which may complicate surgical procedures. For example, patients may experience immune-mediated colitis, dermatitis, or pneumonitis, all of which require careful management to ensure patient safety. An interdisciplinary approach, involving close collaboration between surgical oncologists, immunologists, and anesthesiologists, is essential for addressing these challenges effectively [56].

Strategies for integrating immunotherapy with surgical procedures are evolving, with a focus on maximizing the therapeutic benefits while minimizing risks. One approach is to use intraoperative imaging and real-time assessments to guide surgical decisions [57]. Advanced imaging techniques, such as intraoperative MRI or ultrasound, can help surgeons visualize the extent of the tumor and assess its response to immunotherapy [58]. This allows for more precise resections and can potentially improve outcomes by ensuring that all cancerous tissue is removed.

In addition to technical considerations, the timing of surgery in relation to immunotherapy administration is crucial [59]. Optimal scheduling can enhance the effectiveness of both treatments. For instance, allowing sufficient time for the immune system to mount a robust response before surgery can improve tumor shrinkage and resectability [60]. Conversely, delaying surgery too long after neoadjuvant immunotherapy might reduce its benefits and increase the risk of disease progression [46,59]. Balancing these factors requires a tailored approach based on individual patient characteristics and responses to treatment.

Finally, the role of surgical debulking in the context of immunotherapy is an area of active investigation. Surgical debulking involves the removal of as much of the tumor mass as possible, which can reduce the tumor burden and potentially enhance the efficacy of subsequent immunotherapy [61,62]. This approach is particularly relevant for patients with metastatic or advanced melanoma [61], where complete surgical resection is not feasible. By combining surgical debulking with immunotherapy, clinicians aim to improve overall treatment outcomes and extend survival for these patients.

Postoperative Immunotherapy

Administering immunotherapy after surgery, known as adjuvant immunotherapy, is a critical strategy for improving long-term outcomes in melanoma patients [63]. The primary goal of adjuvant immunotherapy is to eliminate residual microscopic disease that may not be detectable at the time of surgery. By continuing to stimulate the immune system postoperatively, adjuvant immunotherapy helps maintain an anti-tumor response, reducing the risk of recurrence and potentially increasing overall survival rates [64].

Clinical trials have shown that adjuvant treatment with immune checkpoint inhibitors, such as nivolumab and pembrolizumab, significantly improves relapse-free survival in patients with high-risk melanoma [39]. These agents work by blocking inhibitory pathways in the immune system, allowing T-cells to remain active and continue attacking cancer cells [39]. The success of these treatments has led to their approval for use in the adjuvant setting for melanoma patients who have undergone complete surgical resection [65].

Monitoring and managing immune-related side effects post-surgery is crucial to the success of adjuvant immunotherapy. While these treatments are generally well-tolerated, they can cause a range of side effects due to heightened immune activity. Common adverse



Figure 3: A schematic representation of the interaction between the melanoma tumor, cellular immune system and the pembrolizumab.

effects include skin rashes, colitis, hepatitis, and endocrinopathies [66]. Early detection and management of these side effects are essential to prevent complications and ensure that patients can continue with their treatment regimen. Regular follow-up visits and close communication between the oncology team and the patient are vital components of postoperative care.

The long-term outcomes and survival rates for patients receiving adjuvant immunotherapy are promising [67]. Studies have demonstrated that patients who receive adjuvant immunotherapy after surgery have a lower risk of disease recurrence and better overall survival compared to those who do not receive such treatment [39]. These findings underscore the importance of adjuvant immunotherapy as a standard component of care for high-risk melanoma patients [65]. Additionally, ongoing research continues to explore the optimal duration and combination of adjuvant treatments to maximize their efficacy.

Clinical trials and real-world evidence have highlighted the need for personalized approaches in adjuvant immunotherapy. Not all patients respond equally to treatment, and factors such as tumor genetics, the presence of specific biomarkers, and the patient's overall health can influence outcomes. Personalized treatment plans that take these variables into account can help optimize the effectiveness of adjuvant immunotherapy [68,69]. Biomarker-driven strategies, such as using PD-L1 expression levels to guide treatment decisions, are an area of active investigation and hold promise for further enhancing patient outcomes [70].

In conclusion, adjuvant immunotherapy plays a vital role in the postoperative management of melanoma, offering significant benefits in terms of relapse-free survival and overall outcomes. The integration of these therapies into standard care practices requires careful management of side effects and personalized treatment approaches. As research progresses, the continued refinement of adjuvant immunotherapy strategies will likely lead to even better outcomes for melanoma patients, ultimately improving their quality of life and survival rates.

Clinical Trials and Evidence

The integration of immunotherapy with surgical treatment for melanoma has been extensively studied in clinical trials [10,71,72], providing a robust body of evidence supporting its efficacy. These trials have explored various aspects of combining immunotherapy with surgery, including neoadjuvant and adjuvant approaches, patient selection criteria, and the impact on survival rates and recurrence. The results from these trials have significantly influenced clinical practice and guidelines, highlighting the transformative potential of this combined therapeutic strategy.

One of the landmark trials in this area is the CheckMate 238 study, which evaluated the efficacy of nivolumab *vs.* ipilimumab as adjuvant therapy in patients with resected stage III or IV melanoma [73,74]. This phase III trial demonstrated that nivolumab significantly improved recurrence-free survival compared to ipilimumab, with a better safety profile. These findings led to the approval of nivolumab as an adjuvant treatment for melanoma, setting a new standard in postoperative care for high-risk patients.

Another pivotal study is the KEYNOTE-054 trial, which assessed pembrolizumab as adjuvant therapy in resected high-risk stage III melanoma patients [39]. The trial results showed that pembrolizumab significantly prolonged recurrence-free survival compared to placebo. This study provided compelling evidence for the use of pembrolizumab in the adjuvant setting and has been instrumental in shaping current treatment protocols for melanoma patients' post-surgery (Figure 3).

Neoadjuvant immunotherapy has also been the focus of several important clinical trials. The OpACIN and OpACIN-neo trials explored the use of neoadjuvant combination therapy with nivolumab and ipilimumab in patients with stage III melanoma [75]. These studies revealed that neoadjuvant therapy induced higher rates of pathological complete response compared to adjuvant therapy alone. The trials also highlighted the potential of neoadjuvant immunotherapy to convert inoperable tumors into resectable ones, thereby improving surgical outcomes and overall survival rates.

The NADIM trial further underscored the benefits of neoadjuvant immunotherapy in melanoma. This study investigated the combination of nivolumab and ipilimumab as neoadjuvant treatment followed by surgery in patients with stage III melanoma [76-78]. The trial reported high rates of major pathological response, suggesting that preoperative immunotherapy can effectively reduce tumor burden and enhance surgical success. These findings support the growing consensus that neoadjuvant immunotherapy can play a crucial role in the management of advanced melanoma.

In addition to these specific trials, a meta-analysis of multiple studies has provided comprehensive insights into the overall efficacy of combining immunotherapy with surgery. This meta-analysis indicated that both neoadjuvant and adjuvant immunotherapy significantly improve recurrence-free survival and overall survival compared to surgery alone [79,80]. The analysis also highlighted the importance of personalized treatment strategies, emphasizing that patient selection and biomarker-driven approaches are key to optimizing outcomes.

Emerging data from ongoing trials continue to expand our understanding of the best practices for integrating immunotherapy with surgical treatment. For example, the PRADO trial is evaluating the use of personalized neoadjuvant immunotherapy based on tumor biomarker profiles to tailor treatment regimens for individual patients [81,82]. Early results suggest that this approach can further enhance the efficacy of neoadjuvant therapy, providing a roadmap for more personalized and effective melanoma treatment strategies.

The evidence from these clinical trials underscores the transformative potential of combining immunotherapy with surgery in the treatment of melanoma. By improving recurrence-free survival and overall survival rates, these combined approaches offer new hope for patients with high-risk and advanced melanoma. As research continues to evolve, the integration of immunotherapy and surgical treatment is likely to become increasingly refined, leading to even better outcomes and setting new standards in melanoma care.

Challenges and Considerations

Integrating immunotherapy with surgical treatment for melanoma presents several challenges and considerations that need to be addressed to optimize patient outcomes. One of the primary challenges is identifying patients who will benefit most from combined therapy. Not all melanoma patients respond equally to immunotherapy, and factors such as tumor genetics, the presence of specific biomarkers, and the patient's overall health can significantly influence treatment efficacy. Personalized treatment plans that incorporate biomarker-driven strategies are essential for selecting the right candidates for combined therapy. Research into predictive biomarkers, such as PD-L1 expression levels, tumor mutational burden, and specific genetic mutations, is ongoing and holds promise for refining patient selection criteria.

Another significant challenge is the management of immune-related Adverse Effects (irAEs) [83,84]. Immunotherapy can trigger a range of side effects due to the heightened activity of the immune system. These side effects can vary from mild to severe and include conditions such as colitis, dermatitis, pneumonitis, hepatitis, and endocrinopathies [84]. The management of these adverse effects requires a multidisciplinary approach, involving oncologists, immunologists, and other specialists. Early detection and intervention are crucial to mitigating the impact of irAEs and ensuring that patients can continue their treatment regimen without significant interruptions [85]. This necessitates regular monitoring and prompt management of symptoms.

The cost and accessibility of immunotherapeutic agents pose another significant challenge. Immunotherapy, particularly immune checkpoint inhibitors, can be expensive, limiting access for many patients [86]. The financial burden of treatment, coupled with the costs of managing side effects and the need for frequent follow-up, can be substantial. Strategies to reduce costs and improve access to these life-saving treatments are critical [87]. This includes advocating for policy changes, exploring alternative funding mechanisms, and ensuring that healthcare systems are equipped to support the comprehensive care that immunotherapy patients require.

Addressing immune resistance and relapse is another critical consideration [88]. Despite the successes of immunotherapy, some patients develop resistance to treatment, leading to disease progression and relapse [89,90]. Understanding the mechanisms of immune resistance is a major focus of current research [90]. Factors such as changes in the tumor microenvironment, loss of antigen presentation, and the development of immune escape mechanisms contribute to resistance. Ongoing studies aim to identify strategies to overcome resistance, such as combination therapies that include other immune-modulating agents, targeted therapies, or radiation.

The integration of immunotherapy with surgical procedures also presents logistical challenges [46,91]. The timing and sequencing of treatments must be carefully coordinated to maximize therapeutic benefits while minimizing risks [92]. For example, the interval between neoadjuvant immunotherapy and surgery must be optimized to ensure sufficient tumor response without delaying surgical intervention. Similarly, the scheduling of adjuvant immunotherapy post-surgery requires careful planning to allow for adequate recovery while maintaining the anti-tumor immune response. Multidisciplinary teams must work closely to develop and implement these treatment plans effectively.

Furthermore, the variability in response to immunotherapy across different patient populations highlights the need for inclusive research. Most clinical trials have primarily included patients from specific demographic groups, often underrepresenting minorities and other populations. Ensuring that diverse patient populations are adequately represented in clinical research is crucial for understanding the full spectrum of immunotherapy responses and for developing treatment protocols that are effective for all patients. Efforts to increase diversity in clinical trials and to study the effects of immunotherapy across various demographic groups are essential steps in this direction [93].

Lastly, patient education and support play a vital role in the successful integration of immunotherapy with surgical treatment. Patients must be adequately informed about the potential benefits and risks of combined therapy, including the possibility of adverse effects and the importance of adherence to follow-up care [94]. Providing comprehensive education and support can empower patients to make informed decisions about their treatment and to actively participate in their care [95]. Support systems, including counseling services, patient advocacy groups, and educational resources, are critical components of holistic patient care.

In conclusion, while the combination of immunotherapy and surgery offers significant promise for improving outcomes

in melanoma patients, it also presents a range of challenges and considerations. Addressing these issues requires a multifaceted approach, involving personalized treatment plans, effective management of adverse effects, strategies to overcome resistance, coordinated treatment scheduling, inclusive research, and robust patient support systems.

Case Studies

Case studies provide valuable insights into the practical application and outcomes of combining immunotherapy with surgical treatment for melanoma. These real-world examples highlight the potential benefits, challenges, and lessons learned from integrating these therapeutic approaches. Detailed presentations of successful case studies can inform future practice and guide clinicians in optimizing treatment strategies.

One notable case study involved a 45-year-old patient with stage III melanoma who received neoadjuvant immunotherapy with nivolumab and ipilimumab [96]. The patient presented with a large, inoperable tumor on the lower leg. After three cycles of the combination immunotherapy, imaging studies revealed significant tumor shrinkage, making surgical resection feasible. The patient underwent surgery with clear margins and achieved a complete pathological response. This case highlights the potential of neoadjuvant immunotherapy to convert inoperable tumors into resectable ones, thereby improving surgical outcomes and overall prognosis.

Another case study focused on a 60-year-old patient with stage IV melanoma who underwent surgical debulking followed by adjuvant pembrolizumab therapy [97]. Despite the advanced stage of the disease, the patient responded well to the combined treatment approach. Postoperative imaging showed no signs of residual disease, and the patient remained in remission for over two years. This example underscores the importance of adjuvant immunotherapy in managing high-risk patients and reducing the likelihood of recurrence.

A third case study involved a 50-year-old patient with recurrent melanoma who had previously undergone multiple surgeries and traditional therapies [98]. The patient was treated with a combination of surgery and neoadjuvant pembrolizumab. The neoadjuvant therapy resulted in significant tumor reduction, facilitating a less extensive surgical procedure. Post-surgery, the patient received adjuvant pembrolizumab, which helped maintain remission. This case demonstrates the potential for combined therapy to offer new hope for patients with recurrent disease, providing durable responses even after multiple lines of prior treatment.

The complexity of managing immune-related adverse effects was highlighted in a case study of a 55-year-old patient with stage III melanoma. The patient received neoadjuvant nivolumab and experienced immune-mediated colitis. Despite this complication, the multidisciplinary team managed the adverse effect effectively, allowing the patient to proceed with surgery. The tumor was successfully resected, and the patient continued with adjuvant nivolumab, achieving a sustained response. This case illustrates the importance of early detection and management of side effects to ensure continuity of treatment and positive outcomes.

A case study involving a 47-year-old patient with melanoma metastases to the lymph nodes explored the use of personalized neoadjuvant therapy based on tumor biomarker profiles [99,100]. The patient was treated with neoadjuvant nivolumab, selected due to high PD-L1 expression levels. The treatment resulted in a major pathological response, allowing for a less invasive lymph node dissection [100]. This personalized approach not only enhanced surgical outcomes but also minimized postoperative complications. The case underscores the value of biomarker-driven strategies in tailoring treatment plans for individual patients.

Another compelling case involved a 65-year-old patient with melanoma brain metastases. The patient received neoadjuvant ipilimumab and nivolumab, leading to significant reduction in brain lesions [101]. This allowed for a successful neurosurgical intervention, followed by adjuvant immunotherapy to prevent recurrence. The patient achieved a remarkable response, with no evidence of disease progression at one-year follow-up. This case highlights the potential of immunotherapy to manage challenging metastatic sites and improve surgical feasibility.

In conclusion, these case studies demonstrate the diverse applications and significant benefits of integrating immunotherapy with surgical treatment for melanoma. They highlight the importance of personalized approaches, effective management of adverse effects, and the potential for improved surgical outcomes and long-term survival.

Conclusion

Integrating immunotherapy with surgical treatment for melanoma represents a promising frontier in cancer therapy, combining the strengths of both modalities to improve patient outcomes. This manuscript has explored the various aspects of this approach, from historical perspectives and mechanisms of action to clinical trials, challenges, and case studies. The evidence highlights the transformative potential of combining these therapies to enhance survival rates and quality of life for melanoma patients.

The synergy between immunotherapy and surgery lies in their complementary mechanisms. Immunotherapy, particularly immune checkpoint inhibitors, activates the immune system to target and destroy melanoma cells, while surgery physically removes the tumor burden. Preoperative (neoadjuvant) immunotherapy can shrink tumors, making them more resectable and potentially leading to better surgical outcomes. Postoperative (adjuvant) immunotherapy aims to eliminate residual disease and prevent recurrence, further enhancing long-term survival.

Clinical trials have consistently shown that integrating immunotherapy with surgery leads to significant improvements in recurrence-free and overall survival rates. Landmark studies such as CheckMate 238 and KEYNOTE-054 have established the efficacy of adjuvant nivolumab and pembrolizumab, respectively, in reducing recurrence in high-risk melanoma patients. Neoadjuvant trials, including OpACIN and NADIM, have demonstrated that preoperative immunotherapy can induce high rates of pathological complete response, transforming inoperable tumors into resectable ones.

Case studies provide valuable insights into the practical application of combined therapy, illustrating the potential benefits and challenges encountered in real-world settings. These examples highlight the importance of a multidisciplinary approach, involving close collaboration between surgical oncologists, medical oncologists,

immunologists, and other specialists to tailor treatment plans and manage complications effectively.

Despite the promising results, the integration of immunotherapy and surgery presents several challenges. Identifying patients who will benefit most from combined therapy, managing immune-related adverse effects, and addressing cost and accessibility issues are critical considerations. Personalized treatment plans that incorporate biomarker-driven strategies are essential for optimizing outcomes. Moreover, effective management of adverse effects and careful coordination of treatment timing are crucial for ensuring patient safety and maximizing therapeutic benefits.

Looking forward, the continued refinement of immunotherapy and surgical strategies will likely lead to even better outcomes for melanoma patients. Ongoing research into predictive biomarkers, novel immunotherapeutic agents, and combination therapies holds promise for further enhancing the efficacy of these treatments. Additionally, efforts to increase the diversity of clinical trial populations will ensure that findings are applicable to a broader range of patients, ultimately improving care for all.

In conclusion, the integration of immunotherapy with surgical treatment for melanoma offers a powerful approach to improving patient outcomes. The combined therapy leverages the strengths of both modalities, providing a comprehensive strategy to combat melanoma. As research and clinical practice continue to evolve, the insights gained from clinical trials, case studies, and real-world experiences will guide the development of more effective and personalized treatment protocols, paving the way for a new era in melanoma care.

References

1. Hasan N, Nadaf A, Imran M, Jiba U, Sheikh A, Almalki WH, et al. Skin cancer: Understanding the journey of transformation from conventional to advanced treatment approaches. Mol Cancer. 2023;22(1):168.
2. Wang S, Liu Y, Feng Y, Zhang J, Swinnen J, Li Y, et al. A review on curability of cancers: More efforts for novel therapeutic options are needed. Cancers (Basel). 2019;11(11):1782.
3. Chaft, JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021;18(9):547-57.
4. Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol. 2024;41(2):51.
5. Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, et al. Inhibitors of immune checkpoints–PD-1, PD-L1, CTLA-4–new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev. 2021;40(3):949-82.
6. Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, et al., Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021;51(3):544-56.
7. Benitez JC, Remon J, Besse B. Current panorama and challenges for neoadjuvant cancer immunotherapy. Clin Cancer Res. 2020;26(19):5068-77.
8. Liu X, Xing H, Liu H, Chen J. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. Asia Pac J Clin Oncol. 2022;18(4):335-43.
9. Gao S, Yang X, Xu J, Qiu N, Zhai G. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: The horizons in cancer treatment. ACS nano. 2021;15(8):12567-603.
10. O'Donnell JS, Hoefsmit EP, Smyth MJ, Blank CU, Teng MWL. The promise of neoadjuvant immunotherapy and surgery for cancer treatment. Clin Cancer Res. 2019;25(19):5743-51.
11. Park CG, Hartl CA, Schmid D, Carmona EM, Kim HJ, Goldberg MS. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018;10(433):eaar1916.
12. Cornelius LA, Fields RC, Tarhini A. Multidisciplinary care of BRAF-mutant stage III melanoma: A physicians perspective review. Oncologist. 2021;26(9):e1644-51.
13. Moss NS, Beal K, Tabar V. Brain metastasis–A distinct oncologic disease best served by an integrated multidisciplinary team approach. JAMA Oncol. 2022;8(9):1252-4.
14. Lopes J, Rodrigues CMP, Gaspar MM, Reis CP. Melanoma management: from epidemiology to treatment and latest advances. Cancers (Basel). 2022;14(19):4652.
15. Joyce D, Skitzki JJ. Surgical management of primary cutaneous melanoma. Surg Clin North Am. 2020;100(1):61-70.
16. Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: A meta-analysis. Ann Surg Oncol. 2014;21(3):717-30.
17. Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, et al. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014;9(1):57.
18. Tardelli E, Mazzarri S, Rubello D, Gennaro M, Fantechi L, Duce V, et al. Sentinel lymph node biopsy in cutaneous melanoma: standard and new technical procedures and clinical advances. A systematic review of the literature. Clin Nucl Med. 201;41(12):e498-507.
19. Kinami S, Nakamura N, Tomita Y, Miyata T, Fujita H, Ueda N, et al. Precision surgical approach with lymph-node dissection in early gastric cancer. World J Gastroenterol. 2019;25(14):1640-52.
20. Morrison S, Han D. Re-evaluation of sentinel lymph node biopsy for melanoma. Curr Treat Options Oncol. 2021;22(3):22.
21. Hoption Cann SA, Van Netten JP, Van Netten C. Dr William Coley and tumor regression: A place in history or in the future. Postgrad Med J. 2003;79(938):672-80.
22. Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18(1):155.
23. Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.
24. Chen R, Tao Y, Xu X, Shan L, Jiang H, Yin Q, et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in the treatment of advanced non-small cell lung cancer. Discov Med. 2018;26(143):155-66.
25. Alexander CA, Yang YY. Harnessing the combined potential of cancer immunotherapy and nanomedicine: A new paradigm in cancer treatment. Nanomedicine. 2022;40:102492.
26. Ottaviano M, De Placido S, Ascierto PA. Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma. Virchows Arch. 2019;474(4):421-32.
27. Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy. Front Oncol. 2021;11:641428.
28. D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, et al. Manipulation of the immune system for cancer defeat: A focus on the T

cell inhibitory checkpoint molecules. Curr Med Chem. 2020;27(15):2402-48.

29. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044-60.

30. Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or backups. Nat Immunol. 2019;20(11):1425-34.

31. Rosskopf S, Leitner J, Zlabinger GJ, Steinberger P. CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses *in vitro*. Cancer Immunol Immunother. 2019;68(8):1359-68.

32. Coillie SV, Wiernicki B, Xu J. Molecular and cellular functions of CTLA-4. Adv Exp Med Biol. 2020;1248:7-32.

33. Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509-28.

34. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.

35. Newnes HV, Armitage JD, Audsley KM, Bosco A, Waithman J. Directing the future breakthroughs in immunotherapy: The importance of a holistic approach to the tumor microenvironment. Cancers (Basel). 2021;13(23):5911.

36. Hu Y, Ren SY, Wang RY, Zeng C, Li JN, Xiao P, et al. Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable non-small cell lung cancer. Front Oncol. 2021;11:684070.

37. Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S, et al. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer. 2023;11(1):e005924.

38. van den Bijgaart RJE, Schuurmans F, Fütterer JJ, Verheij M, Cornelissen LAM, Adema GJ. Immune modulation plus tumor ablation: Adjuvants and antibodies to prime and boost anti-tumor immunity in situ. Front Immunol. 2021;12:617365.

39. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J Clin Oncol. 2020;38(33):3925-36.

40. Schneider AK, Chevalier MF, Derré L. The multifaceted immune regulation of bladder cancer. Nat Rev Urol. 2019;16(10):613-30.

41. Qu X, Zhou D, Lu J, Qin D, Zhou J, Liu HJ. Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. Bioact Mater. 2022;24:136-52.

42. Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, et al. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett. 2020;470:126-33.

43. Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.

44. Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Neoadjuvant immunotherapy for NSCLC: Current concepts and future approaches. J Thorac Oncol. 2020;15(8):1281-97.

45. Bilusic M. What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy? Expert Rev Anticancer Ther. 2022;22(6):561-3.

46. Krishnamoorthy M, Lenehan JG, Vareki SM. Neoadjuvant immunotherapy for high-risk, resectable malignancies: Scientific rationale and clinical challenges. J Natl Cancer Inst. 2021;113(7):823-32.

47. Chmielewska I, Stencel K, Kalinka E, Ramlau R, Krawczyk P. Neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer-Clinical trials experience. Cancers (Basel). 2021;13(20):5048.

48. Lucas MW, Versluis JM, Rozeman EA, Blank CU. Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma. Nat Rev Clin Oncol. 2023;20(6):408-22.

49. Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science. 2020;367(6477):eaax0182.

50. Friedlaender A, Naidoo J, Banna GL, Metro G, Forde P, Addeo A, et al. Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treat Rev. 2022;104:102350.

51. Tang Q, Zhao S, Zhou N, He J, Zu L, Liu T, et al. PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors. Int J Oncol. 2023;62(4):49.

52. Adam T, Becker TM, Chua W, Bray V, Roberts TL. The multiple potential biomarkers for predicting immunotherapy response-finding the needle in the haystack. Cancers (Basel). 2021;13(2):277.

53. Eggermont AMM, Hamid O, Long GV, Luke JJ. Optimal systemic therapy for high-risk resectable melanoma. Nat Rev Clin Oncol. 2022;19(7):431-9.

54. De Camilli A. Fischer G. Newer cancer therapies and implications for the perioperative period. Curr Oncol. 2023;30:7638-53.

55. Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell. 2021;184(6):1575-88.

56. Rezaei N. Cancer treatment: An Interdisciplinary approach. Springer. 2023.

57. Lauwerends LJ, van Driel PBAA, de Jong RJB, Hardillo JAU, Koljenovic S, Puppels G, et al. Real-time fluorescence imaging in intraoperative decision making for cancer surgery. Lancet Oncol. 2021;22(5):e186-95.

58. Bastos DCDA, Juvekar P, Tie Y, Jowkar N, Pieper S, Wells WM, et al. Challenges and opportunities of intraoperative 3D ultrasound with neuronavigation in relation to intraoperative MRI. Front Oncol. 2021;11:656519.

59. Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth MJ, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology. 2019;8(5):e1581530.

60. Mountzios G, Remon J, Hendriks LEL, Garcia-Campelo R, Rolfo C, Schil PV, et al. Immune-checkpoint inhibition for resectable non-small-cell lung cancer-Opportunities and challenges. Nature Rev Clinical Oncol. 2023;20(10): 664-77.

61. Hishida T, Masai K, Kaseda K, Asakura K, Asamura H. Debulking surgery for malignant tumors: The current status, evidence and future perspectives. Japanese J clinical oncol. 2021;51(9):1349-62.

62. Flanigan RC. Debulking nephrectomy in metastatic renal cancer. Clin Cancer Res. 2004;10(18 Pt 2):6335S-41S.

63. Testori AAE, Ribero S, Indini A, Mandalà M. Adjuvant treatment of melanoma: recent developments and future perspectives. Am J Clin Dermatol. 2019;20(6):817-27.

64. Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects. Genes Dis. 2020;7(3):359-69.

65. Spagnolo F, Andrea Boutros A, Tanda E, Queirolo P. The adjuvant treatment revolution for high-risk melanoma patients. in Seminars in Cancer Biology. Semin Cancer Biol. 2019;59:283-9.

66. Patrinely JR, Johnson R, Lawless AR, Bhave P, Sawyers A, Dimitrova M, et al. Chronic immune-related adverse events following adjuvant anti–PD-1

therapy for high-risk resected melanoma. JAMA Oncol. 2021;7(5):744-8.

67. Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B, et al. Long-term survival, quality of life, and psychosocial outcomes in advanced melanoma patients treated with immune checkpoint inhibitors. J Oncol. 2019;5269062.

68. Jain KK. Personalized immuno-oncology. Textbook of Personalized Medicine. 2021. p. 479-508.

69. Yang L, Yang J, Kleppe A, Danielsen HE, Kerr DJ. Personalizing adjuvant therapy for patients with colorectal cancer. Nat Rev Clin Oncol. 2024;21(1):67-79.

70. Wu M, Huang Q, Xie Y, Wu X, Ma H, Zhang Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade *via* combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.

71. Naik PP. Current trends of immunotherapy in the treatment of cutaneous melanoma: A review. Dermatol Ther (Heidelb). 2021;11(5):1481-96.

72. Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. J Hematol Oncol. 2017;10:1-9.

73. Larkin J, Del Vecchio M, Mandalá M, Gogas H, Fernandez AM, Dalle S, et al. Adjuvant nivolumab versus ipilimumab in resected stage III/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238. Clin Cancer Res. 2023;29(17):3352-61.

74. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma N Engl J Med. 2017;377(19):1824-35.

75. Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RP, van Houdt WJ, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol. 2023;34(4):420-30.

76. Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non–small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924-33.

77. Bogatsa E, Lazaridis G, Stivanaki C, Timotheadou E. Neoadjuvant and adjuvant immunotherapy in resectable NSCLC. Cancers (Basel). 2024;16(9):1619.

78. Chen LN, Wei AZ, Shu CA. Neoadjuvant immunotherapy in resectable non-small-cell lung cancer. Ther Adv Med Oncol. 2023;15:17588359231163798.

79. Thomas D, Bello DM. Adjuvant immunotherapy for melanoma. J Surg Oncol. 2021;123(3):789-97.

80. Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin Cancer Res. 2020;26(12):2838-48.

81. Reijers IL, Menzies AM, Van Akkooi AC, Versluis JM, Van Den Heuvel NM, Saw RP, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial. Nat Med. 2022;28(6):1178-88.

82. Reijers I, Rozeman EA, Menzies AM, Van De Wiel BA, Eriksson H, Suijkerbuijk K, et al. Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial. American Society of Clinical Oncology. 2019.

83. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P, Chandra AB. Current diagnosis and management of immune related Adverse Events (irAEs) induced by immune checkpoint inhibitor therapy Front Pharmacol. 2017;8:49.

84. Park R, Lopes L, Saeed A. Outcomes following immunotherapy re-challenge after immune-related adverse event: Systematic review and meta-analysis. Immunotherapy. 2020;12(16):1183-93.

85. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39(36):4073-126.

86. Dobosz P, Stępień M, Golke A, Dzieciątkowski T. Challenges of the immunotherapy: Perspectives and limitations of the immune checkpoint inhibitor treatment. Int J Mol Sci. 2022;23(5):2847.

87. Diaz JV, Riviello ED, Papali A, Adhikari NK, Ferreira JC. Global critical care: Moving forward in resource-limited settings. Ann Glob Health. 2019;85(1):3.

88. Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria JC. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11(4):874-99.

89. Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat. 2020;53:100718.

90. Bai R, Chen N, Li L, Du N, Bai L, Lv Z. Mechanisms of cancer resistance to immunotherapy. Front Oncol. 2020;10:1290.

91. Konstorum A, Vella AT, Adler AJ, Laubenbacher RC. Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. J R Soc Interface. 2017;14(131):20170150.

92. WHO. Compendium of WHO guidelines and associated standards: Ensuring optimum delivery of the cascade of care for patients with tuberculosis. World Health Organization. 2018.

93. Oyer RA, Hurley P, Boehmer L, Bruinooge SS, Levit K, Barrett N, et al. Increasing racial and ethnic diversity in cancer clinical trials: An American Society of Clinical Oncology and Association of Community Cancer Centers joint research statement. J Clin Oncol. 2022;40(19):2163-71.

94. Bakos O, Lawson C, Rouleau S, Tai LH. Combining surgery and immunotherapy: Turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 2018;6(1):86.

95. Barbosa HC, de Queiroz Oliveira JA, da Costa JM, de Melo Santos RP, Miranda LG, de Carvalho Torres H, et al. Empowerment-oriented strategies to identify behavior change in patients with chronic diseases: An integrative review of the literature. Patient Educ Couns. 2021;104(4):689-702.

96. Lim AM, Cavanagh K, Hicks RJ, McLean L, Goh MS, Webb A, et al. Delayed Response after confirmed progression (DR) and other unique immunotherapy-related treatment concepts in cutaneous squamous cell carcinoma. Front Oncol. 2021;11:656611.

97. Kim JS, Chang E, Demirci H. Novel treatment strategies for malignant anterior segment tumors, in global perspectives in ocular oncology. Springer. 2023;291-309.

98. Alqahtani S, Alhefdhi AY, Almalik O, Anwar I, Mahmood R, Mahasin Z, et al. Primary oral malignant melanoma metastasis to the brain and breast: A case report and literature review. Oncol Lett. 2017;14(2):1275-80.

99. Sessions C. Nottingham Pathology 2016. J Pathol. 2016;240:S1-48.

100. Vos JL, Elbers JB, Krijgsman O, Traets JJ, Qiao X, van der Leun AM, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat Commun. 2021;12(1):7348.

101. Hays P, Hays P. Advancing healthcare through personalized medicine. Great strides in precision medicine: Personalized oncology, immunotherapies, and molecular diagnostics. Springer. 2021;141-417.